Skip to main content
Year archive

Heidelberg Pharma AG — 2011 filings

All 28 regulatory filings released by Heidelberg Pharma AG (HPHA) in 2011, sourced directly from the official regulator.

28 Filings
2011 Period
2011 filings (28)
Filing Released Lang
WILEX AG: WILEX and IBA report on follow up meeting with the FDA on further steps in the development of REDECTANE(R)
Legal Proceedings Report
2011-12-14 English
WILEX AG: WILEX Inc. lists Oncogene Science(R) CA IX IHC Kit as an In-Vitro-Diagnostic with the FDA
Regulatory Filings
2011-12-07 English
WILEX AG: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX(R)
Earnings Release Q4 2012
2011-11-21 English
WILEX AG: ARISER Independent Data Monitoring Committee (IDMC) recommends conducting the final analysis of the pivotal Phase III trial with RENCAREX(R)
Legal Proceedings Report
2011-11-21 English
Q2 Report 2010/2011
Interim / Quarterly Report H2 2011
2011-10-31 German
Declaration of Voting Results & Voting Rights Announcements 2011
Declaration of Voting Results & Voting Rights Announcements
2011-10-25 English
WILEX AG reports an adjustment of the goodwill of Heidelberg Pharma AG according to IFRS
Legal Proceedings Report
2011-10-15 English
WILEX AG publishes 9-month financial report 2011
Earnings Release 9M 2011
2011-10-13 English
WILEX AG: WILEX Inc. and ALPCO Diagnostics sign marketing and distribution agreement for North America
Regulatory Filings
2011-10-10 English
WILEX AG: FDA grants Fast Track designation to WILEX's RENCAREX(R) for the adjuvant therapy of clear cell Renal Cell Carcinoma
Regulatory Filings
2011-10-05 English
WILEX AG: WILEX starts first oral Phase I study with MEK inhibitor WX-554
Regulatory Filings
2011-09-15 English
WILEX's subsidiary WILEX Inc. receives ISO certification
Environmental & Social Information
2011-08-03 English
WILEX AG announces successful half year results
Earnings Release H1 2011
2011-07-14 English
WILEX AG: WILEX and IBA report on the Pre-BLA Meeting with the FDA and the next steps
Legal Proceedings Report
2011-06-17 English
WILEX AG reports on the Pre-BLA Meeting with the FDA and the next steps in the REDECTANE(R) approval process
Regulatory Filings
2011-06-17 English
WILEX AG: Patient recruitment in Phase II breast cancer trial with MESUPRON(R) successfully completed
Regulatory Filings
2011-05-05 English
WILEX AG grants exclusive US commercialisation rights for RENCAREX(R) to Prometheus
M&A Activity
2011-05-02 English
WILEX AG grants exclusive US commercialisation rights for RENCAREX(R) to
Regulatory Filings
2011-04-30 English
WILEX AG publishes financial report for the first quarter of 2011
Earnings Release Q1 2011
2011-04-13 English
Q1 Report 2010/2011
Interim / Quarterly Report Q1 2011
2011-04-13 German
Declaration of Voting Results & Voting Rights Announcements 2011
Declaration of Voting Results & Voting Rights Announcements
2011-04-07 English
Wilex AG: Bekanntmachung der Einberufung zur Hauptversammlung am 18.05.2011 in Munchen mit dem Ziel der europaweiten Verbreitung gema 121 AktG
AGM Information
2011-04-07 German
WILEX AG: Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2011-03-31 English
WILEX AG reports on the successful financial year 2010
Earnings Release FY 2010
2011-02-22 English
Annual Report 2009/2010
Annual Report FY 2010
2011-02-22 German
Report Publication Announcement 2011
Report Publication Announcement
2011-02-14 English
WILEX AG announces start of interim analysis for its Phase III ARISER registration trial with RENCAREX(R)
Legal Proceedings Report
2011-01-24 English
Declaration of Voting Results & Voting Rights Announcements 2011
Declaration of Voting Results & Voting Rights Announcements
2011-01-13 English